Skip to content

Long-term effects of ipragliflozin on diabetic nephropathy and blood pressure in patients with type 2 diabetes

Long-term effects of ipragliflozin on diabetic nephropathy and blood pressure in patients with type 2 diabetes - Long-term effects of ipragliflozin on diabetic nephropathy and blood pressure in patients with type 2 diabetes

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000031157
Enrollment
50
Registered
2018-02-05
Start date
2014-05-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes with diabetic nephropathy

Interventions

None listed

Sponsors

Ogawa Red Cross Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with type 2 diabetes 2. HbA1c higher than 6.5% and lower than 11.0% 3. BMI higher than 22 and lower than 45 kg/m2 4. Patients who have been treated diet/exercise therapy alone, or patients treated with oral anti-diabetic drugs without SGLT2 inhibitor and/or insulin therapy at baseline. 5. Patients who are able to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who have history or current serious diabetic complication. 2. Patients that insulin dependence is suspected. 3. Patients who have history or current cardiac failure (New York Heart Association Class III or IV), myocardial infarction or cerebrovascular disorder. 4. Patients whose eGFR lower than 45 mL/min/1.73m2, serum creatinine higher than 1.5 mg/dL. 5. Patients who have hepatic dysfunction.

Design outcomes

Primary

MeasureTime frame
Changes in HbA1c

Secondary

MeasureTime frame
Changes from baseline in urinary albumin-to-creatinine ratio (UACR), eGFR, blood pressure, body weight, fasting plasma glucose, fasting serum lipids, AST, ALT, and uric acid at week 104.

Countries

Japan

Contacts

Public ContactDaisuke Ito

Ogawa Red Cross Hospital Department of Internal Medicine

dito@saitama-med.ac.jp0493-72-2333

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026